An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

NCT07197866

Status	RECRUITING
Phase	Phase 2
Sponsor	Teva Branded Pharmaceutical Products R&D LLC
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (5)

- Completion of the treatment period and the week 48(V9) visit of the double-blind trial (TV56286-NDG-20039) whilst remaining compliant with trial requirements
- Females of childbearing potential may be included only if they have a negative pregnancy test at the baseline visit
- Females of childbearing potential whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods for the duration of the trial and for 28 days after the last does of IMP
- Males who are potentially fertile/reproductively competent (not surgically \[eg, vasectomy\] or congenitally sterile) and their female partners who are of childbearing potential must use, together with their female partners, highly effective birth control methods for the duration of the trial and for 28 days after the last dose of investigational medicinal product
- NOTE - Additional criteria apply, please contact the investigator for more information

Exclusion (4)

- Is a female participant who is pregnant, plans to become pregnant, or is breastfeeding during the trial
- Is of a vulnerable population (eg, people kept in detention or jail)
- Is using or consuming any prohibited concomitant medications within the specified exclusionary windows of this trial
- Note - Additional criteria apply, please contact the investigator for more information

Locations (9 total)

Teva Investigational Site 15544, Boca Raton, Florida, United States
Teva Investigational Site 15555, Tampa, Florida, United States
Teva Investigational Site 15543, Spokane, Washington, United States
... and 6 more locations